Browsing Tag
Tirzepatide
37 posts
Cirius Therapeutics shows 0602K and tirzepatide combo preserves muscle and burns fat in obesity and type 2 diabetes
Cirius Therapeutics unveils new ADA 2025 data showing MPC inhibitor 0602K significantly improves muscle and fat metabolism when combined with tirzepatide.
Can Lilly’s flat $499/month Zepbound pricing reshape obesity drug access in the U.S.?
Lilly expands Zepbound access via LillyDirect, offering all FDA-approved doses for $499/month. Explore the implications for patients and the GLP-1 drug market.
Gan & Lee Pharmaceuticals begins US Phase 2 trial of bofanglutide for obesity and weight management
Gan & Lee Pharmaceuticals (Shanghai Stock Exchange: 603087) has initiated its Phase 2 clinical trial of bofanglutide (GZR18)…
More affordable Zepbound? Lilly’s new pricing plan shakes up obesity treatment
Eli Lilly and Company (Lilly) has introduced new single-dose vials of Zepbound (tirzepatide), expanding treatment options for self-pay…
Palatin Technologies completes Phase 2 obesity trial with MC4R bremelanotide and GLP-1/GIP tirzepatide
Palatin Technologies, Inc. has announced the completion of its Phase 2 BMT-801 clinical trial, a study evaluating the…
Why BioAge Labs’ promising obesity drug trial of azelaprag came to an abrupt halt
BioAge Labs, a clinical-stage biopharmaceutical company focused on metabolic disease research, has announced the discontinuation of its STRIDES…
This diabetes breakthrough drug slashes risk by 94%—discover how tirzepatide is transforming obesity treatment
Eli Lilly and Company (NYSE: LLY) has released compelling results from the SURMOUNT-1 study, which highlights that tirzepatide…
Eli Lilly’s tirzepatide shows promising results for obstructive sleep apnea in latest clinical trials
Eli Lilly and Company (NYSE: LLY) has announced promising results from the SURMOUNT-OSA phase 3 clinical trials of…
Eli Lilly’s tirzepatide shows promising results in MASH treatment study
Eli Lilly and Company (NYSE: LLY) revealed compelling outcomes from the SYNERGY-NASH study, showcasing significant efficacy of tirzepatide…
Lilly announces significant results in SURMOUNT-OSA trials of tirzepatide in OSA
Eli Lilly and Company (NYSE: LLY) has released positive topline results from the phase 3 SURMOUNT-OSA clinical trials,…